Results 181 to 190 of about 6,510 (202)

Paxlovid (nirmatrelvir/ritonavir).

WMJ : official publication of the State Medical Society of Wisconsin, 2022
Kristin, Busse, Abir T, El-Alfy
openaire   +1 more source

Nifedipine/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19

New England Journal of Medicine, 2022
exaly  

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Vaccines, 2022
Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello   +2 more
exaly  

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

Clinical Infectious Diseases, 2023
exaly  

Nirmatrelvir Plus Ritonavir: First Approval

Drugs, 2022
exaly  

Methylprednisolone/nirmatrelvir+ritonavir

Reactions Weekly, 2022
openaire   +1 more source

Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system

Lancet Infectious Diseases, The, 2023
exaly  

Carfilzomib/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Dobutamine/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source